Wissenschaftliche Arbeiten

Prof. Dr. Marıa Del Pılar Laguna Pes

491 Publikationen. Neben jeder Publikation steht die Quelle der Angabe.

Zurück zum Profil

  1. Analysis. J Urol. 2017 Feb;197(2):314-315.

    Quelle: Profilseite auf medipol.com.tr

  2. 330. D.A. Wollin, A.D. Joyce, M. Gupta, M.Y. Wong, M.P. Laguna Pes, S. Gravas, J. Gutierrez, L. Cormio, K. Wang, G.M. Preminger. Antibiotic use and the prevention and management of infectious complications in stone disease. World J Urol. 2017 Feb 3.

    Quelle: Profilseite auf medipol.com.tr

  3. 331. M.P. Laguna Pes. Re: Cost-Effectiveness of Management Options for Small Renal Mass: A Systematic Review. J Urol. 2017 Mar;197(3 Pt 1):602-603.

    Quelle: Profilseite auf medipol.com.tr

  4. 332. E.I.M.L. Liem, J. Baard, E.C.C. Cauberg, M.T.J. Bus, D.M. de Bruin, M.P. Laguna Pes, J.J.M.C.H. de la Rosette, Th.M. de Reijke. Fluorescence in situ hybridization as prognostic predictor of tumor recurrence during treatment with Bacillus Calmette-Guérin therapy for intermediate- and high-risk non-muscle-invasive bladder cancer. Med Oncol. 2017 Sep 2;34(10):172.

    Quelle: Profilseite auf medipol.com.tr

  5. 333. M.J. Scheltema, A.W. Postema, D.M. de Bruin, M. Buijs, M.R. Engelbrecht, M.P. Laguna Pes, H. Wijkstra, Th.M. de Reijke, J.J.M.C.H. de la Rosette. Irreversible electroporation for the treatment of localized prostate cancer: a summary of imaging findings and treatment feedback. Diagn Interv Radiol. 2017 Sep-Oct;23(5):365-370.

    Quelle: Profilseite auf medipol.com.tr

  6. 334. M.P. Laguna Pes. Re: Irreversible Electroporation of Small Renal Masses: Suboptimal Oncologic Efficacy in an Early Series. J Urol. 2017 Sep;198(3):481-482.

    Quelle: Profilseite auf medipol.com.tr

  7. 335. M.P. Laguna Pes. Re: Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline. J Urol. 2017 Sep;198(3):480-482.

    Quelle: Profilseite auf medipol.com.tr

  8. 336. M.P. Laguna Pes. Re: Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. J Urol. 2017 Jul;198(1):36-37.

    Quelle: Profilseite auf medipol.com.tr

  9. 337. M.P. Laguna Pes. Re: Robot-Assisted vs Open Adrenalectomy: Evaluation of Cost-Effectiveness and Peri-Operative Outcome. J Urol. 2017 Jun;197(6):1438.

    Quelle: Profilseite auf medipol.com.tr

  10. 338. M.P. Laguna Pes. Re: Oncologic Outcomes of Kidney-Sparing Surgery versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-Muscle Invasive Bladder Cancer Guidelines Panel. J Urol. 2017 Jun;197(6):1437-1438.

    Quelle: Profilseite auf medipol.com.tr

  11. 339. R.R. Pessoa, R. Autorino, M.P. Laguna Pes, W.R. Molina, D. Gustafson, L. Nogueira, da Silva, P.N. Werahera , F.J. Kim. Laparoscopic Versus Percutaneous Cryoablation of Small Renal Mass: Systematic Review and Cumulative Analysis of Comparative Studies. Clin Genitourin Cancer. 2017;15(5):513-519.

    Quelle: Profilseite auf medipol.com.tr

  12. 340. M.P. Laguna. Re: First-Line Sunitinib versus Pazopanib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma. Database Consortium. J Urol. 2017 Mar;197(3 Pt 1):603.

    Quelle: Profilseite auf medipol.com.tr

  13. 341. M.P. Laguna. Re: Urinary Collecting System Invasion is Associated with Poor Survival in Patients with Clear-Cell Renal Cell Carcinoma. J Urol. 2017 Nov;198(5):976-978.

    Quelle: Profilseite auf medipol.com.tr

  14. 342. M.P. Laguna. Re: Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness. J Urol. 2017 Nov;198(5):977-978.

    Quelle: Profilseite auf medipol.com.tr

  15. 343. M.P. Laguna. Re: Partial Nephrectomy versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-Analysis of Comparative Studies. J Urol. 2017 Dec;198(6):1204-1206.

    Quelle: Profilseite auf medipol.com.tr

  16. 344. M.P. Laguna. Re: Efficacy of Systemic Chemotherapy plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial Carcinoma. J Urol. 2017 Dec;198(6):1205-1206.

    Quelle: Profilseite auf medipol.com.tr

  17. 345. M.P. Laguna. Re: Mortality, Morbidity and Healthcare Expenditures after Local Tumour Ablation or Partial Nephrectomy for T1A Kidney Cancer. J Urol. 2017 Aug;198(2):252-254

    Quelle: Profilseite auf medipol.com.tr

  18. 346. M.P. Laguna. Re: Findings and Impact of Early Imaging after Partial Nephrectomy. J Urol. 2017 Aug;198(2):253-254.

    Quelle: Profilseite auf medipol.com.tr

  19. 347. M.P. Laguna. Re: End-Stage Renal Disease after Renal Surgery in Patients with Normal Preoperative Kidney Function: Balancing Surgical Strategy and Individual Disorders at Baseline. J Urol. 2017 May;197(5):1214-1215.

    Quelle: Profilseite auf medipol.com.tr

  20. 348. M.P. Laguna. Re: Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma. J Urol. 2017 May;197(5):1215.

    Quelle: Profilseite auf medipol.com.tr

  21. 349. J.L Boormans, J. Mayor de Castro, L. Marconi, Y. Yuan, M.P. Laguna Pes, C. Bokemeyer, N. Nicolai, F. Algaba, J. Oldenburg, P. Albers. Testicular Tumour Size and Rete Testis Invasion as Prognostic Factors for the Risk of Relapse of Clinical Stage I Seminoma Testis Patients Under Surveillance: a Systematic Review by the Testicular Cancer Guidelines Panel. Eur Urol. 2017 Nov 20. pii: S0302-2838(17)30826-6

    Quelle: Profilseite auf medipol.com.tr

  22. 350. M.P. Laguna. Re: A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. J Urol. 2018 Jan;199(1):23-25.

    Quelle: Profilseite auf medipol.com.tr

  23. 351. M.P. Laguna. Re: Surgical Histopathology for Suspected Oncocytoma on Renal Mass Biopsy: A Systematic Review and Meta-Analysis. J Urol. 2018 Jan;199(1):24-25.

    Quelle: Profilseite auf medipol.com.tr

  24. 352. M.P. Laguna. Re: The Impact of Quality Variations on Patients Undergoing Surgery for Renal Cell Carcinoma: A National Cancer Database Study. J Urol. 2018 Feb;199(2):338-339.

    Quelle: Profilseite auf medipol.com.tr

  25. 353. M.P. Laguna. Re: When to Perform Preoperative Chest Computed Tomography for Renal Cancer Staging. J Urol. 2018 Feb;199(2):339.

    Quelle: Profilseite auf medipol.com.tr

  26. 356. A.Basiri, J.J. de la Rosette, S. Tabatabaei, H.H. Woo, M.P. Laguna, H. Shemshaki.Comparison of retropubic, laparoscopic and robotic radical prostatectomy: who is the winner? World J Urol. 2018 Apr;36(4):609-621.

    Quelle: Profilseite auf medipol.com.tr

  27. 357. M.P. Laguna. Re: Stereotactic Ablative Body Radiotherapy for Inoperable Primary Kidney Cancer: A Prospective Clinical Trial. J Urol. 2018 Jun;199(6):1393-1394.

    Quelle: Profilseite auf medipol.com.tr

  28. 358. M.P. Laguna. Re: Randomized Phase III Trial of Adjuvant Pazopanib versus Placebo after Nephrectomy in Patients with Localized or Locally Advanced Renal Cell Carcinoma. J Urol. 2018 Jun;199(6):1393-1394.

    Quelle: Profilseite auf medipol.com.tr

  29. 359. M.P. Laguna. Re: Stereotactic Ablative Body Radiotherapy for Inoperable Primary Kidney Cancer: A Prospective Clinical Trial. J Urol. 2018 Jun;199(6):1393-1394.

    Quelle: Profilseite auf medipol.com.tr

  30. 360. M.P. Laguna. Re: Randomized Phase III Trial of Adjuvant Pazopanib versus Placebo after Nephrectomy in Patients with Localized or Locally Advanced Renal Cell Carcinoma. J Urol. 2018 Jun;199(6):1393-1394.

    Quelle: Profilseite auf medipol.com.tr

  31. 361. M.P. Laguna. Re: Recommendations for the Management of Rare Kidney Cancers. J Urol. 2018 May;199(5):1109.

    Quelle: Profilseite auf medipol.com.tr

  32. 362. M.P. Laguna. Re: Intravenous Mannitol versus Placebo during Partial Nephrectomy in Patients with Normal Kidney Function: A Double-Blind, Clinically-Integrated, Randomized Trial. J Urol. 2018 May;199(5):1108-1109.

    Quelle: Profilseite auf medipol.com.tr

  33. 363. M.P. Laguna. Re: Defining the Role of Intraoperative Transesophageal Echocardiography during Radical Nephrectomy with Inferior Vena Cava Tumor Thrombectomy for Renal Cell Carcinoma. J Urol. 2018 Apr;199(4):890.

    Quelle: Profilseite auf medipol.com.tr

  34. 364. M.P. Laguna. Re: Impact of Diagnostic Ureteroscopy on Intravesical Recurrence in Patients Undergoing Radical Nephroureterectomy for Upper Tract Urothelial Cancer: A Systematic Review and Meta-Analysis. J Urol. 2018 Apr;199(4):889-890.

    Quelle: Profilseite auf medipol.com.tr

  35. 366. M.P. Laguna. Re: Pathological Heterogeneity in Sporadic Synchronous RenalTumors: Is the Histological Concordance Predictable? J Urol. 2018 Oct;200(4):694-695.

    Quelle: Profilseite auf medipol.com.tr

  36. 367. M.P. Laguna. Re: Incidence of T3a Up-Staging and Survival after Partial Nephrectomy: Size-Stratified Rates and Implications for Prognosis. J Urol. 2018 Oct;200(4):695.

    Quelle: Profilseite auf medipol.com.tr

  37. 368. L. Sandbergen, S. Guven, M.P. Laguna. Can ablation win against partial nephrectomy and become first line therapy in cT1a renal tumours? Curr Opin Urol. 2019 Jan;29(1):70-77.

    Quelle: Profilseite auf medipol.com.tr

  38. 369. M.P. Laguna. Re: A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma. J Urol. 2018 Nov;200(5):941-942.

    Quelle: Profilseite auf medipol.com.tr

  39. 370. M.P. Laguna. Re: Patients' Preferences for Adjuvant Sorafenib after Resection of Renal Cell Carcinoma in the SORCE Trial: What Makes it Worthwhile? J Urol. 2018 Sep;200(3): 494-496.

    Quelle: Profilseite auf medipol.com.tr

  40. 371. M.P. Laguna. Re: Perioperative Morbidity of Lymph Node Dissection for Renal Cell Carcinoma: A Propensity Score-Based Analysis. J Urol. 2018 Sep;200(3):495-496.

    Quelle: Profilseite auf medipol.com.tr

  41. 372. M.P. Laguna. Re: The Role of Lymph Node Dissection in the Management of Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. J Urol. 2019 Jan;201(1):26-27.

    Quelle: Profilseite auf medipol.com.tr

  42. 373. M.P. Laguna. Re: Oncologic Outcomes of Patients with Positive Surgical Margin after Partial Nephrectomy: A 25-Year Single Institution Experience. J Urol. 2019 Jan; 201(1) :27-28

    Quelle: Profilseite auf medipol.com.tr

  43. 374. M.P. Laguna. Re: Outcomes of Pathologic Stage T3a Renal Cell Carcinoma Up-Staged from Small Renal Tumor: . J Urol. 2019 Feb;201(2):224-225

    Quelle: Profilseite auf medipol.com.tr

  44. 375. M.P. Laguna. Re: Molecular Subtypes of Clear-Cell Renal Cell Carcinoma Are Prognostic for Outcome after Complete Metastasectomy. J Urol. 2019 Apr;201(4):664-665

    Quelle: Profilseite auf medipol.com.tr

  45. 377. T. Deng, Y. Chen, B. Liu, M.P. Laguna, J.J.M.C.H. de la Rosette, X. Duan, W. Wu, G. Zeng. systematic review and cumulative analysis of the managements for proximal impacted ureteral stones. World J Urol. 2019 Aug;37(8):1687-1701

    Quelle: Profilseite auf medipol.com.tr

  46. 378. M.P. Laguna. Re: The Probability of Aggressive versus Indolent Histology Based on Renal Tumor Size: Implications for Surveillance and Treatment. J Urol. 2019 May;201(5):856

    Quelle: Profilseite auf medipol.com.tr

  47. 379. M.P. Laguna. Re: Time Trends in Service Provision and Survival Outcomes for Patients with Renal Cancer Treated by Nephrectomy in England 2000-2010. J Urol. 2019 May;201(5):855

    Quelle: Profilseite auf medipol.com.tr

  48. 380. M.P. Laguna. Re: Comparative Effectiveness of Management Options for Patients with Small Renal Masses: . J Urol. 2019 Mar;201(3):439

    Quelle: Profilseite auf medipol.com.tr

  49. 381. M.P. Laguna. Re: Active Surveillance for Localized Renal Masses: . J Urol. 2019 Mar;201(3):440.

    Quelle: Profilseite auf medipol.com.tr

  50. 382. M.P. Laguna. Re: Adjuvant Vascular Endothelial Growth Factor-Targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. J Urol. 2019 Jun;201(6):1050-1051

    Quelle: Profilseite auf medipol.com.tr